180 related articles for article (PubMed ID: 28210112)
1. Azacitidine and decitabine have different mechanisms of action in non-small cell lung cancer cell lines.
Nguyen AN; Hollenbach PW; Richard N; Luna-Moran A; Brady H; Heise C; MacBeth KJ
Lung Cancer (Auckl); 2010; 1():119-140. PubMed ID: 28210112
[TBL] [Abstract][Full Text] [Related]
2. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.
Hollenbach PW; Nguyen AN; Brady H; Williams M; Ning Y; Richard N; Krushel L; Aukerman SL; Heise C; MacBeth KJ
PLoS One; 2010 Feb; 5(2):e9001. PubMed ID: 20126405
[TBL] [Abstract][Full Text] [Related]
3. Effects of DNA methyltransferase inhibitors (DNMTIs) on MDS-derived cell lines.
Tsujioka T; Yokoi A; Uesugi M; Kishimoto M; Tochigi A; Suemori S; Tohyama Y; Tohyama K
Exp Hematol; 2013 Feb; 41(2):189-97. PubMed ID: 23085465
[TBL] [Abstract][Full Text] [Related]
4. Systematic discovery of drug action mechanisms by an integrated chemical genomics approach: identification of functional disparities between azacytidine and decitabine.
Hsieh YY; Huang TC; Lo HL; Jhan JY; Chen ST; Yang PM
Oncotarget; 2016 May; 7(19):27363-78. PubMed ID: 27036028
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study.
Hu N; Qin T; Du X; Wang B; Wang X; Xu Z; Pan L; Qu S; Xiao Z
Med Sci Monit; 2021 Jan; 27():e928454. PubMed ID: 33514682
[TBL] [Abstract][Full Text] [Related]
6. Adult T-cell leukemia-lymphoma acquires resistance to DNA demethylating agents through dysregulation of enzymes involved in pyrimidine metabolism.
Yoshida-Sakai N; Watanabe T; Yamamoto Y; Ureshino H; Kamachi K; Kurahashi Y; Fukuda-Kurahashi Y; Kimura S
Int J Cancer; 2022 Apr; 150(7):1184-1197. PubMed ID: 34913485
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines.
Qin T; Jelinek J; Si J; Shu J; Issa JP
Blood; 2009 Jan; 113(3):659-67. PubMed ID: 18931345
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
9. Decitabine: 2'-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716.
Drugs R D; 2003; 4(6):352-8. PubMed ID: 14584964
[TBL] [Abstract][Full Text] [Related]
10. Decitabine and 5-azacitidine both alleviate LPS induced ARDS through anti-inflammatory/antioxidant activity and protection of glycocalyx and inhibition of MAPK pathways in mice.
Huang X; Kong G; Li Y; Zhu W; Xu H; Zhang X; Li J; Wang L; Zhang Z; Wu Y; Liu X; Wang X
Biomed Pharmacother; 2016 Dec; 84():447-453. PubMed ID: 27685787
[TBL] [Abstract][Full Text] [Related]
11. Use of hypomethylating agents and associated care in patients with myelodysplastic syndromes: a claims database study.
Hatoum HT; Lin SJ; Buchner D; Kim E
Curr Med Res Opin; 2011 Jun; 27(6):1255-62. PubMed ID: 21554144
[TBL] [Abstract][Full Text] [Related]
12. Decitabine: 2'-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716.
Drugs R D; 2003; 4(3):179-84. PubMed ID: 12757405
[TBL] [Abstract][Full Text] [Related]
13. Changes in Apoptotic Pathways in MOLM-13 Cell Lines after Induction of Resistance to Hypomethylating Agents.
Janotka Ľ; Messingerová L; Šimoničová K; Kavcová H; Elefantová K; Sulová Z; Breier A
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669837
[TBL] [Abstract][Full Text] [Related]
14. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
15. Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC).
DeZern AE; Zeidan AM; Barnard J; Hand W; Al Ali N; Brown F; Zimmerman C; Roboz GJ; Garcia-Manero G; Steensma DP; Komrokji RS; Sekeres MA;
Leuk Lymphoma; 2017 Jun; 58(6):1325-1331. PubMed ID: 27774847
[TBL] [Abstract][Full Text] [Related]
16. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G
Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133
[TBL] [Abstract][Full Text] [Related]
17. Effect of cytarabine and decitabine in combination in human leukemic cell lines.
Qin T; Youssef EM; Jelinek J; Chen R; Yang AS; Garcia-Manero G; Issa JP
Clin Cancer Res; 2007 Jul; 13(14):4225-32. PubMed ID: 17634552
[TBL] [Abstract][Full Text] [Related]
18. Decitabine induces cell cycle arrest at the G1 phase via p21(WAF1) and the G2/M phase via the p38 MAP kinase pathway.
Lavelle D; DeSimone J; Hankewych M; Kousnetzova T; Chen YH
Leuk Res; 2003 Nov; 27(11):999-1007. PubMed ID: 12859993
[TBL] [Abstract][Full Text] [Related]
19. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
[TBL] [Abstract][Full Text] [Related]
20. Novel prodrugs of decitabine with greater metabolic stability and less toxicity.
Hattori N; Sako M; Kimura K; Iida N; Takeshima H; Nakata Y; Kono Y; Ushijima T
Clin Epigenetics; 2019 Aug; 11(1):111. PubMed ID: 31370878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
